Schizoaffective Disorder Clinical Trial
Official title:
Metabolic Side Effects, Diet and Exercise Counseling and Brain Function in a Naturalistic Clinical Trial of Clozapine for Treatment Resistant Bipolar and Schizoaffective Disorder
Bipolar Disorder (BD) and Schizoaffective Disorder (SA) clients.
- determine if after 12 months of treatment with clozapine, the BMI changes with clients
who are councelled as usual regarding weight gain while on Clozapine.
- determine if after 12 months of treatment with clozapine, the BMI changes with intense,
structured councelling about diet and exercise.
Status | Completed |
Enrollment | 48 |
Est. completion date | July 2011 |
Est. primary completion date | July 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Clients diagnosed with bipolar disorder or schizoaffective disorder - Clients who respond poorly to treatment - Males and females ages 18 years or older - Clients who have had a trial of antipsychotics, incl. at least one atypical antipsychotic plus at least 2 mood stabilizers - Clients who are capable of providing informed consent Exclusion Criteria: - Clients who take carbamazepine - Clients with a history of extremely low white blood counts - Clients with severe kidney, liver or heart disease, or heart operation - Clients are hypersensitive to clozapine - Clients who have a history of serious side effects after previous treatment with clozapine - Clients with alcohol or drugs abuse within the last 3 months - Clients who have a seizure disorder - Clients who have metal in the head, neck or eyes, shrapnel, bullets, or body piercing, a pacemaker, brain aneurism clips, cochlear implant, hearing aid, tens unit, spinal implant, or pregnancy. These safety measures are necessary because of the magnetic fields of the MRI scan. |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Canada | St. Joseph's Healthcare, Centre for Mountain Health Services | Hamilton | Ontario |
Lead Sponsor | Collaborator |
---|---|
St. Joseph's Healthcare Hamilton |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Increases in BMI in subjects with BD and SA after 12 months of clozapine treatment will be smaller in subjects treated with CBT ex/diet compared with those receiving CAU. | 5 years | No | |
Secondary | Adverse changes in plasma lipids, blood sugar, and fitness level will be greater in subjects treated with CBT ex/diet compared with those receiving CAU after 12 months of clozapine treatment. | 5 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT01878513 -
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis
|
N/A | |
Recruiting |
NCT05030272 -
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
|
N/A | |
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Not yet recruiting |
NCT04551027 -
Assessing the Effect of Compensatory Cognitive Intervention Among People With Severe Mental Illness
|
N/A | |
Completed |
NCT02901587 -
Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder
|
Phase 1 | |
Terminated |
NCT02796144 -
MEtformin and Lorcaserin for WeighT Loss in Schizophrenia
|
Phase 4 | |
Completed |
NCT02160249 -
RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia)
|
N/A | |
Recruiting |
NCT02986490 -
Magnesium Variations and Cardiometabolic Risk in Patients With Antipsychotic Drugs
|
N/A | |
Completed |
NCT02417142 -
Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia
|
Phase 4 | |
Terminated |
NCT02234752 -
Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia
|
Phase 2 | |
Completed |
NCT02091388 -
Bioavailability of LY03004 and Risperdal® Consta®
|
Phase 1 | |
Completed |
NCT01992393 -
Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME)
|
N/A | |
Completed |
NCT01945333 -
Personalized and Scalable Cognitive Remediation Approaches
|
N/A | |
Completed |
NCT01975584 -
Neuroendocrine and Immune Response to Stress in Schizophrenia
|
N/A | |
Terminated |
NCT02149823 -
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
|
Phase 1 | |
Completed |
NCT01683539 -
Understanding How Cognitive Remediation Works
|
N/A | |
Completed |
NCT01658150 -
Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder
|
N/A | |
Completed |
NCT01193153 -
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
|
Phase 3 |